# reload+after+2024-01-21 18:46:26.400021
address1§322 11th Avenue SW
address2§Suite 804
city§Calgary
state§AB
zip§T2R 0C5
country§Canada
phone§403 670 7377
website§https://www.oncolyticsbiotech.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
fullTimeEmployees§29
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Matthew C. Coffey M.B.A., Ph.D.', 'title': 'President, CEO & Director', 'fiscalYear': 2022, 'totalPay': 783825, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kirk J. Look C.A., CA', 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'totalPay': 553867, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Thomas C. Heineman M.D., Ph.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'totalPay': 652421, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Allison  Hagerman P.Eng., P.M.P.', 'title': 'Vice President of Product Development', 'fiscalYear': 2022, 'totalPay': 435224, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Jon  Patton', 'title': 'Director of Investor Relations & Communication', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John Mark Lievonen F.C.A., FCA, LLD', 'title': 'Consultant', 'fiscalYear': 2022, 'totalPay': 19420, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§2
compensationRisk§8
shareHolderRightsRisk§2
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.421
currency§USD
dateShortInterest§1702598400
forwardEps§-0.41
exchange§NCM
quoteType§EQUITY
shortName§Oncolytics Biotech Inc.
longName§Oncolytics Biotech Inc.
firstTradeDateEpochUtc§1002288600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§caa6aa30-46b4-3d5c-af3a-fafc49e0c736
gmtOffSetMilliseconds§-18000000
targetHighPrice§4.99
targetLowPrice§4.49
targetMeanPrice§4.87
targetMedianPrice§4.99
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§3.996
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
